BillionToOne ctDNA Test Matches Tumor-Informed Assay in New Study
A peer-reviewed study finds BillionToOne's tissue-free Northstar Response achieved 94% concordance with tumor-informed ctDNA testing for cancer monitoring.
A newly published peer-reviewed study has found that BillionToOne's tissue-free liquid biopsy test, Northstar Response, performs on par with — and in some cases better than — tumor-informed circulating tumor DNA (ctDNA) assays for monitoring cancer treatment response.
The head-to-head comparison recorded 94% concordance between the two approaches. In every case where the two tests disagreed, clinical ground-truth data sided with Northstar Response, suggesting the tissue-free method may carry a diagnostic edge in ambiguous scenarios.
Read more MAIA Biotechnology Hits Key Enrollment Goals in Lung Cancer Trials →
The significance of the finding lies in what Northstar Response does not require: tumor tissue. Tumor-informed assays typically demand a prior biopsy to sequence a patient's cancer before a personalized monitoring test can be designed, a process that adds time and logistical complexity to care. A tissue-free alternative that matches that performance could broaden access to ctDNA-based monitoring for patients who lack accessible tissue samples.
Liquid biopsy technology, which detects cancer signals through a standard blood draw, has seen rapid clinical adoption as oncologists seek non-invasive ways to track whether treatments are working or whether disease is returning. The ability to do so without tumor-informed customization represents a meaningful workflow simplification for cancer centers.
The study adds to a growing body of evidence evaluating next-generation sequencing-based ctDNA platforms against one another in real-world clinical settings. Continue reading at GlobeNewswire - Industry News on Financial Services.
